Compare Elastic NV (ESTC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Illumina, Inc. — how do they compare? Elastic NV trades at $75.22 (market cap $7.94B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 3.7× Elastic NV's market cap, and Illumina, Inc. is trading nearer its 52-week high, Elastic NV nearer its low. Which is the better fit depends on your goals.
| ESTC | ILMN | |
|---|---|---|
Market Cap | $7.94B | $29.12B |
Sector | Technology | Health |
52-Week High | $94.47 | $205.10 |
52-Week Low | $43.30 | $91.00 |
Enterprise Value | $7.16B | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic N.V. (ESTC) trades at $75.11, up 7.38% in the past 24 hours, with a bullish technical signal and strong analyst consensus. Recent earnings beats, including Q1 2026 EPS of $0.61 versus $0.561 expected, highlight operational strength. The company announced AI collaborations with OpenAI and AWS security distinctions, driving positive sentiment.
Outlook remains positive due to growth prospects in AI and security, but risks include high valuation multiples and ongoing legal investigations. The stock offers upside to the consensus price target of $74.21, though investors should weigh profitability improvements against competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
